



Biolux Research Announces Launch of the OsseoPulse™ Bone Regeneration System in Canada.

VANCOUVER, B.C., CANADA – Oct. 31, 2008 – Biolux Research Ltd. is pleased to announce today that it has launched the OsseoPulse™ Bone Regeneration System in Canada. The product is now available for sale through Citagenix Inc., our exclusive distribution partner. The product has been approved by Health Canada as a class II medical device, and received a medical device license earlier in 2008. Production quality has been proven, sales training has taken place, and product has been shipped to Citagenix to begin marketing and sales.

“We are thrilled to have reached this milestone in our company development, the launch of our breakthrough product,” states Kevin Strange, President and CEO of Biolux. “Tremendous efforts have been invested into development of the OsseoPulse™, and it has been well-received in discussions with early adopters and thought leaders. Our clinical work has shown better than expected results in terms of accelerating bone regeneration and implant stability, and thus reducing time to load implants. We look forward to working with Citagenix in commercializing the OsseoPulse™ in Canada.”

Michael McMillan, Vice President Sales and Marketing of Citagenix, states that “we are excited by the prospect of marketing the OsseoPulse™, as it is a very innovative approach to accelerating bone regeneration in dental implantology. The entire market has a clear desire to reduce the time for implant treatment, and the OsseoPulse™ meets that pressing need. The product complements our existing product line of grafting and membrane regeneration products, and our sales force has the skills and experience necessary to help launch this new product.”

About Biolux Research

Biolux Research Ltd. is a world leader in the development of light accelerated regeneration systems for dentistry. Biolux focuses on product development, clinical and basic research, and its proprietary, patent-pending OsseoPulse™ Bone Regeneration System is premised on a vision to transform the practice of implantology and oral surgery in dentistry by accelerating implant integration and bone regeneration in a safe, effective and non-invasive approach. www.bioluxresearch.com

About Citagenix

Founded in 1997 in Montreal, Citagenix Inc. has become the largest source of knowledge and experience in the Canadian medical device industry when it comes to dental bone regeneration. Citagenix is a fully integrated innovative medical device company led by a highly experienced senior management and advisory team. They successfully commercialize their dental products through direct sales in Canada. It is their strategy to focus on developing or acquiring and commercializing new and novel medical devices with significant commercial potential, strong social and economic benefits, targeted at demand driven markets. www.citagenix.com.

For More Information:

Kevin Strange
President & CEO
Biolux Research Ltd.
+1 (250) 686-1120
k.strange@bioluxresearch.com